CVS/Caremark Merger Expected To Close Promptly Following Shareholder Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Caremark shareholders vote in favor of CVS’ roughly $27 billion acquisition, ending Express Scripts’ hostile bid for the pharmacy benefit manager.
You may also be interested in...
Actavis Executive VP-U.S. Commercial And Administration Doug Boothe: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Boothe talks with “The Pink Sheet” DAILY about follow-on biologics and other issues facing the generics industry, as well as how the top-five generics company is positioning itself to thrive in an evolving global environment.
Actavis Executive VP-U.S. Commercial And Administration Doug Boothe: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Boothe talks with “The Pink Sheet” DAILY about follow-on biologics and other issues facing the generics industry, as well as how the top-five generics company is positioning itself to thrive in an evolving global environment.
CVS Evaluating 90-Day Prescriptions At Retail Option
Following CVS’ merger with Caremark, the drug store chain is reviewing ways to make drug dispensing more convenient for consumers.